Lymphoblastic leukemia/lymphoma (ALL/LBL) is an aggressive form of non-Hodgkin lymphoma (NHL) affecting B-or T-cells, respectively. The serum level of soluble interleukin-2 receptor (sIL-2R) is known to reflect the immune activity and tumor volume in aggressive NHL; however, the release of sIL-2R in LBL has not been extensively studied. Further, the relationship between sIL-2R release with the expression level of IL-2R α subunit (CD25) remains unknown. In the present study, we examined the serum level of sIL-2R in 23 patients with T-LBL and compared these to the levels in 20 patient with T acute lymphoblastic leukemia (T-ALL), 40 patients with diffuse large B-cell lymphoma (DLBCL) and 40 patients with peripheral T-cell lymphoma, not otherwise specified (PTCL). The release of sIL-2R into the serum in T-LBL patients was significantly lower than that for T-ALL, DLBCL, and PTCL (P < 0.001). Immunohistochemistry revealed that CD25 expression was correlated with the serum level of sIL-2R in T-LBL (P = 0.0069), whereas no correlation was found to exist between serum sIL-2R levels and CD25 expression in DLBCL (P = 0.348) and PTCL 
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Introduction
Lymphoblastic leukemia/lymphoma (ALL/LBL) is caused by neoplasm of immature B or T-cells and can affect numerous tissues, including bone marrow, blood, and sometimes nodal and extranodal sites. LBL accounts for approximately 2% of all lymphomas and is a subtype of aggressive non-Hodgkin lymphoma (NHL). Notably, immune activity and tumor volume in NHL has been linked to the serum levels of soluble interleukin-2 receptor (sIL-2R).
1 Elevation of serum sIL-2R expression has been reported in patients with a variety of hematological malignancies, such as adult T-cell leukemia/lymphoma (ATLL), Hodgkin's lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), and peripheral T-cell lymphoma not otherwise specified (PTCL), [2] [3] [4] [5] [6] as well as in patients with solid malignancies and autoimmune disorders . [7] [8] [9] sIL-2R consists of three non-covalently associated subunits, α (CD25), β (CD122), and γ (CD132). To the best of our knowledge, there have been only a few reports on the serum levels of sIL-2R and CD25 expression in malignant lymphoma 10, 11 and only one report on the serum levels of sIL-2R in LBL patients. 12 Furthermore, the relationship between serum sIL-2R levels and CD25 expression in LBL is still unknown. In the present study, we compared serum levels of CD25 in T-LBL, T-ALL, DLBCL and PTCL, examined CD25 expression in T-LBL, DLBCL, and PTCL patients by immunohistochemical analysis in order Toji, et al 6 to determine the relationship between the histological features of these different lymphomas and serum sIL-2R levels.
Materials and methods

Patient selection
We World Health Organization classification and the cases in each study were reviewed by 4 hematopathologists (K.T., Y.S., T. M-T. and T.Y.). 13 Patients with greater than 25% bone marrow (BM) involvement or more than 5% of the peripheral blood (PB) contained lymphoma cells were excluded to avoid inclusion of patients with leukemia.
Patients in control groups (n= 100) were included 20 patients with T-ALL, 40 patients with DLBCL and 40 patients with PTCL. The sIL-2R serum levels for the control group individuals were measured at the time of initial diagnosis. The patients' serum sIL-2R levels were determined by a commercial laboratory using a sandwich enzyme-linked immunosorbent assay (ELISA). Clinical data were kindly provided by the referring clinicians or obtained from the medical records of the patients. This study Toji, et al 7 was conducted with the approval of the Institutional Review Board of Okayama University, Okayama, Japan. All study procedures were conducted in accordance with the guidelines of the Declaration of Helsinki.
Histological examination and immunohistochemistry
Tissue samples were fixed in 10% formalin and embedded in paraffin. Serial comparisons between the patient groups and the control group were performed using the paired-sample t-test. A p-value less than 0.05 was considered statistically significant.
Results
Comparison of the sIL-2R serum levels in T-LBL, T-ALL, DLBCL, and PTCL patients
The serum levels of each patient were summarized in table 1. The serum levels of sIL-2R measured in T-LBL patients (302 -1,467 U/mL; median 593 U/mL), were significantly lower than those measured for patients with T-ALL (223-4,320 U/mL; median 1,911 U/mL), DLBCL (450 -9,090 U/mL; median 2,805 U/mL; P < 0.001) and PTCL (282 -9890 U/mL; median 3,065 U/mL; P < 0.001) (Fig. 1) . Notably, 20 of T-LBL patients (87%) had sIL-2R serum levels below 1,000 U/mL (Table 1) . 
Immunohistochemical detection of CD25 expression
Tissue morphology of the samples isolated from T-LBL patients is shown in Fig. 2a .
Lymphoblasts were observed to be small to medium-sized with scant cytoplasm, condensed nuclear chromatin, and indistinct nucleoli. Further, all of lymphoblasts were positive for TdT (Fig. 2b) and the T-cell marker CD3 (Fig. 2c) . CD25 expression in these tissues is highlighted in Fig. 2d-2f . The distribution of CD25-positive cells was scattered in the T-LBL patients (Fig. 2d) , whereas a stronger, ubiquitous expression pattern was observed in 33% and 25% of the DLBCL (Fig. 2e ) and PTCL patients (Fig. 2f) , respectively. Similarly, the number of CD25-positive cells in the T-LBL patients (0 -21.75; median 6.5) was significantly lower than that for both the DLBCL patients (40.5 -1735.75; median 251; P < 0.001) and the PTCL patients (2 -966; median 103.25; P < 0.001) ( Table 1) .
Furthermore, double immunohistochemical analysis revealed that CD25-positive cells were TdT negative, CD3 positive, Foxp3 positive, and CD20 negative (Fig. 3a-3d, respectively).
Serum sIL-2R level correlates with CD25 expression
The relationship between serum sIL-2R levels and CD25 expression was examined among the three lymphoma subtypes (T-LBL, DLBCL and PTCL). Fig. 4a shows the correlation curve in T-LBL and, for this subtype, the level of serum sIL-2R and the number of CD25-positive cells were found to be correlated with each other (P = Toji, et al 11 0.0069). On the other hand, no correlation was found to exist between serum sIL-2R levels and CD25 expression in DLBCL ( Fig. 4b ; P = 0.348) and PTCL ( Fig. 4c ; P = 0.266) patients.
Discussion
sIL-2R is a soluble form of the IL-2R α chain. The α chain is expressed on the cell surface of activated lymphocytes and, after secretion, forms sIL-2R. It has been demonstrated that IL-2R is released from the cell surface in a soluble form under particular conditions in vitro and in vivo, 16 and while it is not clear whether neoplastic or non-neoplastic activated T-cells produce sIL-2R, both cell types are thought to have the capacity to release it into the serum. 1, 17 Furthermore, the considerable elevation in serum sIL-2R in malignant lymphoma observed in this study may be caused by the release of this factor from CD25-positive neoplastic cells. 10, 18 In the present study, extremely high levels of serum sIL-2R were observed in several DLBCL patients that also diffusely expressed CD25 in tumor cells, suggesting that these cells could be releasing sIL-2R from their cell membranes in this context. And same cases of DLBCL and PTCL lacking immunohistological expression of CD25 showed high levels of serum sIL-2R. Nakase et al. discussed the possibility that sIL-2R
released from hematological neoplastic cells may be due to not only the shedding of the cell membrane of the CD25-positive neoplastic cells but also active secretion by the CD25-negative inducible neoplastic cells. 2 Therefore, we suspect that both non-neoplastic and neoplastic cells release sIL-2R in DLBCL and PTCL.
We also observed that the serum sIL-2R levels in patients with T-LBL were significantly lower than those of patients with T-ALL, DLBCL and PTCL (P < 0.001). In T-LBL, the CD25-positive T-cells were determined to be non-neoplastic cells. Moreover, these cells were Foxp3-positive, suggesting that they may be non-neoplastic regulatory T-cells. The Foxp3 transcription factor is considered to be the master regulator of regulatory T-cells (T reg ) and, thus, the most specific T reg marker. Furthermore, in the T-LBL patients, the number of CD25-positive cells was correlated with serum sIL-2R levels (P = 0.0069). Yang et al. have also reported that T-cells expressing CD25 are highly represented in B-cell NHL, 19 suggesting that CD25-positive T-cells were the major source of sIL-2R in this type of NHL. 20 In a similar fashion, CD25-positive non-neoplastic T-cells in T-LBL are presumed to be the primary source of sIL-2R, and the low number of cells present results in a lower level of sIL-2R released into the serum compared to the other lymphomas studied here.
In numerous other studies, high levels of sIL-2Rs have been observed in ALL patients. For example, Moon et al. have reported that serum sIL-2R levels were approximately 2,561 ± 2,194 U/ml in ALL patients (n = 39) 21 and the median sIL-2R level in childhood ALL was 2,007 U/mL (267 to 80,000 U/mL; n = 344). 22 Further, Lee et al. also reported that serum sIL-2R levels in ALL patients with CNS invasion averaged 2,987 ± 1,944 U/mL. 23 In the present study, T-ALL patients had statistically significant higher serum sIL-2R levels than T-LBL patients ((P < 0.001, Fig. 1 ). This discrepancy may be caused by the localization and tumor cell volume between ALL and LBL or the existence of BM/PB invasion.
An increased number of infiltrating T reg in tumor tissues has been reported in both carcinoma and lymphoid malignancies and previous studies consistently demonstrate that the number of tumor-infiltrating T reg can be used as a predictor for survival. [24] [25] [26] However investigations including accumulation of cases will be needed.
In conclusion, the release of sIL-2R into the serum in T-LBL patients was significantly lower than in T-ALL, DLBCL and PTCL patients and it correlated with the number of CD25-positive cells. We suspect that the cells secreting sIL-2R in patients with T-LBL might be T reg . Investigation into the detailed role of sIL-2R and T reg and to accumulate more cases will provide us further important about significance of sIL-2R in LBL.
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Take home messages
1. The release of sIL-2R into the serum in T-lymphoblastic lymphoma patients was significantly lower than that for T-acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and peripheral T-cell lymphoma.
2. CD25 expression was correlated with the serum level of sIL-2R in T-lymphoblastic lymphoma.
3. CD25-positive cells were also found to be Foxp3-positive non-neoplastic T-cells.
Figure legends
Fig. 1 The serum sIL-2R levels measured in patients with T-LBL were significantly lower than that found for patients with T-ALL, DLBCL (P < 0.001) and PTCL (P < 0.001). 
